Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apatorsen - Ionis Pharmaceuticals

Next Previous
Drug Profile

Apatorsen - Ionis Pharmaceuticals

Alternative Names: ISIS-306053; OGX-427

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals; University of British Columbia
  • Developer Achieve Life Sciences; Queen Mary Medical School; Sarah Cannon Research Institute
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action HSP27 heat shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bladder cancer

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 01 Oct 2017 Hoosier Cancer Research Network completes the phase II Borealis-2 trial for Bladder cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT01780545)
  • 21 Jun 2017 Hoosier Cancer Research Network terminates a phase II trial in Prostate Cancer (Combination therapy, Metastatic disease) in USA and Canada due to lack of accrual (NCT01681433)
  • 05 May 2017 Sarah Cannon Research Institute and OncoGenex Pharmaceuticals completes the phase II Spruce™ trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (NCT01829113)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top